Researchers reported two advances aimed at overcoming key barriers to CAR‑T efficacy in solid tumors. One study showed that deletion of the nuclear receptor NR2F6 can reinvigorate exhausted CAR‑T cells and restore antitumor immunity in preclinical solid‑tumor models. Separately, a next‑generation CAR‑T design with ultra‑sensitive antigen detection was presented as a strategy to detect low antigen densities typical of many solid cancers. Both approaches tackle distinct obstacles — intrinsic T‑cell exhaustion and limited antigen sensitivity — that have hampered CAR‑T translation beyond hematologic malignancies. The findings lay groundwork for combination engineering strategies and for translating preclinical gains into first‑in‑human testing.